Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $2.8 million.

  • Cytosorbents' Cost of Revenue fell 1602.62% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 629.8%. This contributed to the annual value of $10.5 million for FY2024, which is 1463.92% up from last year.
  • Latest data reveals that Cytosorbents reported Cost of Revenue of $2.8 million as of Q3 2025, which was down 1602.62% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Cost of Revenue registered a high of $4.5 million during Q3 2022, and its lowest value of -$9.9 million during Q4 2022.
  • For the 5-year period, Cytosorbents' Cost of Revenue averaged around $2.1 million, with its median value being $2.5 million (2023).
  • Per our database at Business Quant, Cytosorbents' Cost of Revenue crashed by 41568.38% in 2022 and then surged by 12380.29% in 2023.
  • Over the past 5 years, Cytosorbents' Cost of Revenue (Quarter) stood at $3.1 million in 2021, then plummeted by 415.68% to -$9.9 million in 2022, then soared by 123.8% to $2.3 million in 2023, then rose by 13.21% to $2.7 million in 2024, then increased by 6.12% to $2.8 million in 2025.
  • Its Cost of Revenue stands at $2.8 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.5 million for Q1 2025.